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To gain insight into the regulatory mechanisms underlying the blockade and loss of acetylcholine receptor (AChR) in 
myasthenia, we have followed AChR a-subunit mRNA levels in leg muscles of myasthenic and normal rabbits and rats. 
Northern blots of RNA preparations from normal and myasthenic animals were hybridized with a mouse AChR a-sub- 
unit cDNA probe. Our experiments indicate a specific increase (47-fold) in the levels of a-subunit mRNA in animals 
with experimental autoimmune myasthenia gravis (EAMG), in comparison with control animals. Actin mRNA levels 
were essentially unchanged. Our results thus suggest that EAMG is accompanied by an increased level of AChR gene 
transcription. 
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1. INTRODUCTION 
The nicotinic acetylcholine receptor (AChR) is a 
well characterized ligand gated ion-channel. It 
forms an oligomeric complex of four types of 
subunits present in a molar stoichiometry of ‘Y&J 
[ 1,2]. Special interest in the immunological proper- 
ties of the receptor stems from its involvement as 
the major autoantigen in the autoimmune disease 
myasthenia gravis (MG) and its animal model, ex- 
perimental autoimmune myasthenia gravis 
(EAMG). The disease is accompanied by humoral 
and cellular anti-AChR immune responses and by 
receptor loss [3-51. Although the observations in- 
dicate a net reduction of AChR levels, the 
molecular mechanisms underlying this process, as 
yet, are not clear. The decrease in AChR levels in 
myasthenic muscles may be reflected by similar 
changes in mRNA levels, or alternatively, receptor 
loss may trigger a cascade of compensatory 
mechanisms uch as increasing the rate of protein 
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biosynthesis from pre-existing mRNA and/or 
enhancing the levels of mRNA for the receptor 
subunits. 
It has previously been demonstrated that dener- 
vation of rat diaphragm and mouse leg muscle as 
well as tetrodotoxin treatment of muscle cell 
cultures results in an increase in the levels of 
mRNA encoding for the AChR a-subunit [6-S]. 
This observation has also been extended to the 
mRNA transcripts of the other subunits. The 
mRNA levels of the AChR subunits were shown to 
increase in the course of development in mouse 
[9,10] and calf [ll], and in response to muscle 
denervation in chick [12], rat and mouse [9]. 
In the present study we have followed the level 
of AChR a-subunit mRNA in myasthenic rats and 
rabbits. Based on reactivity with a 32P-labeled 
cDNA probe of the mouse a-subunit, we could 
observe a 4-7-fold increase in the cr-subunit 
mRNA in leg muscles of myasthenic animals. 
2. MATERIALS AND METHODS 
2.1. AChR preparation 
AChR was purified from Torpedo californica electric organ 
(Pacific Bio-Marine, Venice, CA) as described [13]. 
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2.2. Immunological procedures 
Rabbits weighing 2-3 kg were injected in the footpads and in- 
tradermally in three or four spots each with 100 pg purified 
AChR emulsified with complete Freund’s adjuvant (CFA, Dif- 
co) [14]. Animals injected with CFA only were used as controls. 
EAMG was observed in the rabbits by muscular weakness, un- 
coordinated movements, paralysis of the limbs and trunk, and 
difficulties in breathing. Female Lewis rats aged approx. 10 
weeks were each injected in the footpads with 40 pg purified 
AChR in CFA supplemented with 1 mg H37 RA mycobacterium 
(Difco). Rats were boosted intradermally at monthly intervals 
with 40 pg AChR in phosphate-buffered saline (PBS) until 
myasthenic symptoms were observed. Animals injected with 
CFA only were used as controls. 
Rabbit and rat sera were tested for antibodies to purified 
Torpedo AChR by solid-phase radioimmunoassay (SP-RIA) us- 
ing ‘251-labeled protein A to detect antibody binding [15]. 
2.3. RNA isolation and Northern blot analysis 
Rabbits and rats exhibiting EAMG symptoms were killed and 
their leg muscles were frozen in liquid N2 immediately after 
dissection. Total RNA was precipitated in LiWurea essentially 
as in [16], with several modifications. The tissues were 
homogenized in 3 M LiCI, 7 M urea. After 16 h at 4°C the 
pellet was removed by centrifugation at 10000 xg for 30 min 
and resuspended in 0.5% SDS, 10 mM Tris-HCl, pH 7.5, 10 
mM NaCI, and 10 mM EDTA (1 ml/g tissue). An equal volume 
of a buffer containing 0.5% SDS, 10 mM Tris-HCI, pH 7.5, 
0.35 M NaCI, 7 M urea and 10 mM EDTA was added prior to 
phenol extraction and ethanol precipitation. For Northern blot 
analysis 20pg total RNA and 1Osg poly(A)+ RNA obtained by 
purification on oligo-(dT)-cellulose (171 were denatured in for- 
maldehyde at 65°C and subjected to electrophoresis on a 1% 
agarose gel in 16% formaldehyde. RNA was then transferred 
onto Gene Screen Plus membrane filters (NEN, Boston, MA). 
Prehybridization was performed at 42°C for 2 h in 50% for- 
mamide, 5 x SET (0.75 M NaCI, 0.1 M Tris-HCI, pH 7.4, 0.05 
M Trizma base and 0.05 M EDTA), 5 x Denharts (0.1% each of 
I I I I 
/ 
bovine serum albumin, Ficoll and polyvinylpyrrolidone), 1% 
SDS, 50 mM sodium phosphate buffer, pH 6.8, and 40 pg/ml 
heat-denatured salmon sperm DNA. Hybridization was then 
performed at 42°C for 16 h in 50% formamide, SxSET, 
1 x Denharts, 20 mM sodium phosphate, pH 6.8, 10% dextran 
sulfate and 1% SDS. 
2.4. cDNA probes 
The AChR hybridization probe employed was a 900 bp 
NC01 fragment (extending from within the 5’-end to amino 
acid 280) derived from a recombinant DNA plasmid (pMARl5) 
containing the cDNA coding for the a-subunit of mouse AChR 
[18] kindly provided by Dr S. Heinemann. The actin probe was 
a 570 bp insert from plasmid 749 coding for LY-, /3- and y-actins 
[19] kindly provided by Dr U. Nude]. Both probes were labeled 
by nick translation with [a-“P]dATP [20], to a specific activity 
of 1-3x lOa cpm/pg. 
3. RESULTS 
EAMG was induced in rabbits and rats by injec- 
tion of purified AChR from Torpedo electric 
organ. Rabbis displayed myasthenic symptoms of 
muscle weakness 3-4 weeks following a single im- 
munization. Chronic muscle weakness in rats was 
apparent after l-3 boosts of AChR at monthly in- 
tervals. Muscle tissue for RNA preparation as well 
as antisera were sampled from the above animals. 
As shown in fig.1, both rabbits and rats had 
significant anti-AChR antibody titers when killed 
for RNA preparation. We then addressed the ques- 
tion of whether AChR gene expression is altered in 
myasthenic animals. To this end, RNA was ex- 
tracted from leg muscles of normal and myasthenic 
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Fig.1. Binding (solid phase radioimmunoassay) of AChR to rabbit (A) and rat (B) antisera; l , AChR injected animal; 0, CFA 
injected animal. 
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rabbits and rats. Poly(A)+ RNA was prepared by 
passage through an oligo(dT)-cellulose column. 
The RNA preparations were then size fractionated 
on denaturing formaldehyde-agarose gels [21] and 
transferred onto Gene Screen Plus membrane 
filters. To detect AChR a-subunit-specific mRNA, 
Northern blots were probed with the 32P-labeled 
900 bp fragment of the mouse a-subunit cDNA 
clone. in both rabbits and rats a significant in- 
crease in abundance of a-subunit-specific mRNA 
was observed in myasthenic muscles as compared 
to their control counterparts (figs 2,3). Reactivity 
of both myasthenic and normal mRNA prepara- 
tions with an actin-specific probe 1191 was essen- 
tially similar, thus reflecting the selective increase 
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Fig.2. Northern blot analysis of AChR a-subunit transcripts in 
rabbit leg muscle. 10 gg each of poly(A)+ RNA isolated from 
normal (lane 1) and myasthenic (lane 2) rabbit leg muscle were 
denatured in formaldehyde at 65”C, electrophoresed in 1% 
agarose gel containing 16% formaldehyde and transferred to 
Gene Screen Plus membrane filters. These blots were then 
hybridized with the a-subunit cDNA probe from mouse (A) and 
following stripping, with an cu-actin probe (B) as described in 
section 2. For quantitation of the Northern blots densitometric 
scanning was performed. Signals were plotted in arbitrary units 
as a function of the amount of poly(A)+ RNA applied to the 
gel. l , AChR injected rabbits; 0, CFA injected rabbits. 
_A_ 
28S- 
18% 
Fig.3. Distribution of the AChR a-subunit (A) and cu-actin (B) 
mRNAs from normal (1,3) and myasthenic (2,4) rat leg muscle. 
Total RNA (20 pg each in lanes 1.2) and poly(A)+ RNA (10 gg 
each in lanes 3,4) were subjected to blot hybridization as 
described in fig.2. 
in AChR a-subunit mRNA in myasthenic muscle. 
Fig.2 represents autoradiograms of blot 
hybridization analysis of leg muscle poly(A)+ RNA 
from normal and myasthenic rabbits. Quantitation 
of mRNA levels was performed by densitometer 
scanning of the autoradiograms and plotting the 
integral of the scan versus the amount of mRNA 
applied to the gel. Elevation of AChR a-subunit 
mRNA was detected in myasthenic muscles at the 
different amounts of RNA tested (fig.2A). 
Calculated on the basis of densitometric analysis 
this increase amounts to 4-fold. On the other hand, 
the levels of actin mRNA were virtually identical in 
both myasthenic and normal muscles in all 
amounts of RNA tested (fig.2B). 
We also examined the levels of AChR a-subunit 
mRNA in myasthenic rats [22], where the nature of 
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the disease is distinct from that in rabbits. As 
shown in fig.3, mRNA levels of AChR a-subunit 
increase significantly in myasthenic rat muscles as 
compared to normal ones. Based on densitometric 
scanning this increase was calculated to be approx. 
7-fold. Again, an actin-specific probe revealed that 
actin mRNA levels remain unchanged in disease, 
reflecting the selective increase in a-subunit 
transcripts. 
4. DISCUSSION 
Investigation of the molecular regulation of 
AChR expression in myasthenia gravis is of great 
interest. The availability of specific cDNA probes 
for AChR subunits now makes it possible to follow 
AChR gene expression during the course of 
disease. Using an AChR a-subunit cDNA probe, 
we were able to demonstrate increased levels of 
AChR a-subunit mRNA in myasthenic leg muscles 
of both rabbits and rats (figs 2,3). The elevation of 
a-subunit mRNA seems to be selective, as actin 
mRNA levels remain unchanged. 
Previous reports have indicated that the levels of 
surface membrane AChR are reduced in 
myasthenia [23,24]. In addition, accelerated 
degradation of AChR, mediated by anti-AChR an- 
tibodies was observed [25,26]. Although the final 
outcome of myasthenia is decreased surface recep- 
tor levels, it appears that at least with respect to 
AChR a-subunit there is increased mRNA 
transcription. This might reflect a compensatory 
mechanism for receptor loss. It is important to 
analyse the nature and fate of the newly tran- 
scribed AChR mRNA. One should investigate 
whether the observed increase in a-subunit mRNA 
is also seen for the other receptor subunits, 
whether the newly transcribed receptor mRNAs 
reflect the subunit stoichiometry in the protein (i.e. 
a&d) and whether they are translated, and subse- 
quently inserted into the membrane as functional 
receptor molecules. It is also important to deter- 
mine whether the increase in mRNA is triggered by 
anti-AChR antibodies and whether a certain an- 
tibody specificity is required. In this respect it is 
noteworthy that preliminary experiments in our 
laboratory indicate that rabbits immunized with a 
denatured AChR preparation (reduced and car- 
boxymethylated AChR [27]) also had increased 
levels of AChR a-subunit mRNA. As previously 
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demonstrated in our laboratory [14,27] such rab- 
bits displayed high anti-AChR antibody titers but 
had no myasthenic symptoms. These observations 
may indicate that anti-AChR antibodies may lead 
to increased AChR gene transcription without 
necessarily appearance of clinical symptoms of 
myasthenia. It should still be resolved whether the 
phenomenon of increased mRNA levels is directly 
connected to disease, or is a mere result of an im- 
mune response towards an autoantigen. Studies 
are now being performed in our laboratory to 
resolve the issues mentioned above. 
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